Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 182 for:    carfilzomib OR pr-171

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01792102
Recruitment Status : Active, not recruiting
First Posted : February 15, 2013
Last Update Posted : March 5, 2018
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Oncotherapeutics

Brief Summary:
This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib for patients with progressive multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Carfilzomib and Dexamethasone Phase 1 Phase 2

Detailed Description:

This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib for patients with progressive multiple myeloma.

The study will consist of a screening period, followed by a treatment period of up to eight 28-day treatment cycles, followed by a period of maintenance treatment. Subjects are to be treated until disease progression.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma
Study Start Date : April 2013
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018


Arm Intervention/treatment
Experimental: Carfilzomib and Dexamethasone

Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.

Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16.

Drug: Carfilzomib and Dexamethasone

Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.

Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16.

Other Name: Krypolis®




Primary Outcome Measures :
  1. Establish maximum tolerated dose (MTD) [ Time Frame: monthly, up to 24 months ]

    Maximum tolerated dose will be established by the number of dose limiting toxicities and the overall safety and tolerability of the study drug.

    Safety and tolerability will be determined by the following:

    1. incidence and frequency of adverse events throughout the study
    2. clinical laboratory test results at study visits
    3. vital signs measurements at each study visits
    4. medical history and physical examination findings
    5. ECOG performance status at study visits
    6. concomitant medication usage throughout the study


Secondary Outcome Measures :
  1. Establish efficacy as assessed by the overall response rate [ Time Frame: monthly, up to 24 months ]

    Response rate will be determined by the following:

    1. SPEP, UPEP, and quantification of immunoglobulins and immunofixation
    2. bone marrow aspirates and biopsies to confirm CR
    3. roentgenographic skeletal survey

    Response rate will be assessed by the following:

    1. Clinical benefit response rate
    2. Progression-free survival
    3. Time to progression
    4. Duration of response
    5. Overall survival
    6. Pharmacodynamics


Other Outcome Measures:
  1. Relationship of 60-minute infusion of carflizomib with pharmacodynamic markers [ Time Frame: weekly for 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. MM with relapsing or progressive disease at study entry

    a. Defined as progressive MM on patient's last treatment regimen

  2. Measurable disease, as defined by one or more of the following (assessed within 14 days prior to first dose):

    1. Serum M-protein ≥ 0.5 g/dL, or
    2. Urine M-protein ≥ 200 mg/24 hours, or
    3. Only in patients who do not meet a or b, then use serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa/lamda ratio
  3. Age ≥ 18 years
  4. Life expectancy ≥ 6 months
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  6. Adequate hepatic function within 14 days prior to first dose, with bilirubin < 1.5 × the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 × ULN
  7. LVEF ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available.
  8. Absolute neutrophil count (ANC) ≥ 1000/mm3 within 14 days prior to first dose. Screening ANC is to be independent of granulocyte colony stimulating factor support for ≥ 1 week and pegylated granulocyte colony stimulating factor for ≥ 2 weeks.
  9. Hemoglobin ≥ 8.0 g/dL within 14 days prior to enrollment. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed.
  10. Platelet count ≥ 75,000/mm3 (≥ 50,000/mm^3 if myeloma involvement in the bone marrow is > 50%) within 14 days prior to first dose. Patients must not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count
  11. Calculated or measured creatinine clearance (CrCl) of ≥ 15 mL/min within 14 days prior to first dose. Calculation are based on a standard formula, such as the Cockcroft and Gault: [(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if female
  12. Written informed consent in accordance with federal, local, and institutional guidelines
  13. Female patients of childbearing potential (FCBP) must have a negative serum pregnancy test within 14 days prior to first dose and agree to use an effective method of contraception during and for 3 months following last dose of drug (more frequent pregnancy tests may be conducted if required per local regulations). Postmenopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from a pregnancy test
  14. Male patients must agree to use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a FCBP

Exclusion Criteria:

  1. Multiple myeloma of IgM subtype
  2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  3. Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential)
  4. Waldenström's macroglobulinemia
  5. Amyloidosis
  6. Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to first dose
  7. Cytotoxic chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to first dose
  8. Treatment with bortezomib, thalidomide or lenalidomide within 21 days prior to first dose
  9. Focal radiation therapy within 7 days prior to first dose. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (i.e., prior radiation must have been to < 30% of the bone marrow)
  10. Immunotherapy within 21 days prior to first dose
  11. Major surgery within 21 days prior to first dose
  12. Active congestive heart failure (New York Heart Association [NYHA] Classes III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 6 months prior to first dose.
  13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at HBV), or antifungal agents within 14 days prior to first dose
  14. Known human immunodeficiency virus (HIV) seropositivity
  15. Known hepatitis B or C virus infection (except for patients with HBV receiving and responding to HBV antiviral therapy: these patients are allowed)
  16. Patients with known cirrhosis
  17. Second malignancy within the past 3 years, except:

    1. Adequately treated basal cell or squamous cell skin cancer
    2. Carcinoma in situ of the cervix
    3. Prostate cancer < Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months
    4. Breast carcinoma in situ with full surgical resection
    5. Treated medullary or papillary thyroid cancer
    6. Patients with myelodysplastic syndrome
  18. Significant neuropathy (Grades 3 to 4) within 14 days prior to first dose
  19. Peripheral neuropathy with pain ≥ G2 within 14 days prior to first dose
  20. Female patients who are pregnant or lactating
  21. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  22. Prior carfilzomib treatment
  23. Prior participation in any Onyx-sponsored phase 3 trial
  24. Patients with contraindication to dexamethasone
  25. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  26. Ongoing graft-versus-host disease
  27. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
  28. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  29. Any other clinically significant medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01792102


Locations
Layout table for location information
United States, California
James R. Berenson M.D. Inc.
West Hollywood, California, United States, 90069
United States, New Jersey
John Theuer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
Oncotherapeutics
Amgen
Investigators
Layout table for investigator information
Principal Investigator: James Berenson, M.D. James Berenson Inc.
Principal Investigator: Joshua Richter, M.D John Theurer Cancer Center at Hackensack University Medical Center

Layout table for additonal information
Responsible Party: Oncotherapeutics
ClinicalTrials.gov Identifier: NCT01792102     History of Changes
Other Study ID Numbers: IST-CAR-585
First Posted: February 15, 2013    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: March 2018
Keywords provided by Oncotherapeutics:
Multiple Myeloma
Carfilzomib
Krypolis
60 minute infusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors